Publication | Closed Access

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Hematological MalignancyMedicineHematologyClinical TrialsImmunologyMyeloid NeoplasiaMultiple MyelomaPharmacotherapyOral Proteasome InhibitorOpen-label Phase 1/2OncologyRadiation OncologyHealth Sciences